Tenet (THC) Q1 2026 earnings review
Exchange Headwinds Hit Margins Despite CommonSpirit Cash Windfall
Tenet's Q1 GAAP net income surged 73% to $702M, but this was heavily distorted by a $413M revenue recognition from the early conclusion of the CommonSpirit contract. Stripping out this noise, underlying operations are Decelerating. Consolidated Adjusted EBITDA was effectively flat year-over-year (-0.1%), breaking a multi-quarter streak of double-digit growth. The $250M headwind from expiring ACA exchange subsidies—which management warned about last quarter—materialized immediately, causing an unfavorable payer mix that drove Hospital segment earnings down 4.1%. Even the reliable Ambulatory segment (USPI) showed cracks: while revenue grew 10.6%, organic volume fell and margins compressed significantly. Guidance for FY26 suggests a prolonged period of stagnant earnings growth.
🐂 Bull Case
The CommonSpirit deal delivered an immediate $540M cash infusion. Even excluding this, Adjusted Free Cash Flow surged to $978M in Q1, fueling $318M in share repurchases and maintaining a pristine 2.24x leverage ratio.
USPI continues to successfully target high-value procedures. Net revenue per case in the Ambulatory segment grew 5.6%, driving double-digit revenue growth despite flat case counts.
🐻 Bear Case
Lower ACA exchange admissions are destroying payer mix. Hospital Adjusted EBITDA fell 4.1% YoY to $678M, and margins dropped 80 basis points to 16.7%.
The Ambulatory segment is growing via M&A and rate hikes, not volume. Same-facility surgical cases actually declined 0.3%, and segment margin dropped 150 basis points to 36.7%.
⚖️ Verdict: 🔴
Bearish. The core growth engine is sputtering. The massive cash windfall masks the reality that the ACA subsidy expiration is fundamentally damaging the hospital payer mix, and USPI organic volume is going backward. Margin compression across both segments is a clear red flag.
Key Themes
ACA Exchange Subsidies Expiration Bites (Macro)
Management warned in 25Q4 that expiring enhanced premium tax credits could create a $250M EBITDA headwind in 2026. This headwind has arrived. The company explicitly blamed 'unfavorable payer mix due to lower exchange admissions' for flat consolidated EBITDA and falling Hospital segment earnings. This represents a Reversing trend from 2025, where exchange admissions grew 35% in Q1 and drove massive margin expansion.
USPI Volume Stalls & Margins Compress
A specific data point contradicts the bullish growth narrative for Ambulatory Care: same-facility surgical cases declined 0.3% in Q1. While segment revenue grew 10.6% to $1.32B, this was entirely driven by acquisitions and a 5.6% increase in revenue per case (acuity/pricing). Consequently, USPI Adjusted EBITDA margin compressed heavily from 38.2% to 36.7%. The segment is losing its operating leverage.
CommonSpirit Deal Supercharges Capital Returns
The early conclusion of the Conifer/CommonSpirit contract was a masterclass in monetization. Tenet recognized $413M in revenue and received $540M in cash (netting out minority interest redemption). This liquidity event allowed Tenet to aggressively repurchase 1.35 million shares ($318M) in Q1 while keeping net leverage entirely Stable at 2.24x.
High-Acuity Shift Driving Top Line
The deliberate strategy to focus on higher-acuity, complex procedures continues to protect the top line. USPI net revenue per case grew 5.6%. By aggressively shifting high-margin surgeries from inpatient settings to ambulatory surgery centers, Tenet is maximizing revenue per patient encounter.
Disciplined Expense Management
Despite margin compression from bad payer mix, management kept operating costs on a tight leash. Consolidated Adjusted EBITDA remained flat YoY instead of declining precisely because of what management noted as 'expense efficiencies' and disciplined operational control across both segments.
Medicaid Supplemental Tailwind Disappears
Tenet is facing tough year-over-year comparables. Q1 2025 included a $40M favorable pre-tax impact from prior-year Medicaid supplemental revenues. Q1 2026 had zero. This base-effect headwind will persist throughout 2026, making organic earnings growth incredibly difficult to achieve.
Other KPIs
Accelerating significantly from $678M in the prior year. Operating cash flows exploded to $1.64B (aided by the $540M CommonSpirit payment), but even after adjusting for one-time items and $180M in CapEx, cash conversion was phenomenal. This provides massive flexibility for continued M&A and buybacks.
Reversing. Down 4.1% from $707M in 25Q1. While adjusted admissions ticked up 0.6%, revenue per adjusted admission dropped 1.5%. The loss of ACA exchange patients with favorable commercial rates directly eroded the bottom line.
Guidance
Stable to Decelerating. The midpoint of $4.635B represents anemic 1.5% growth over FY25's $4.566B. This formally embeds the $250M headwind from the expiration of enhanced premium tax credits, signaling an earnings plateau.
Decelerating. This is a noticeable step down from the 7.5% full-year growth USPI achieved in 2025. Given that cases declined 0.3% in Q1, achieving this guidance will rely almost entirely on sustained pricing power and high-acuity mix.
Stable. In line with the 0.6% growth seen in Q1, but assumes a slight ramp-up as the year progresses. Given the collapse in ACA exchange volumes, this growth must come from traditional commercial or Medicare volumes.
Key Questions
USPI Margin Degradation
Ambulatory Adjusted EBITDA margin dropped 150 basis points to 36.7%, and same-facility cases fell 0.3%. How much of this margin compression is structural cost inflation versus case mix, and is a sub-37% margin the new normal?
Quantifying the ACA Floor
You cited lower exchange admissions as a primary driver of the Hospital segment's 4.1% earnings decline. Have we found the floor on enrollment attrition, or do you expect this unfavorable payer mix to worsen in Q2 and Q3?
M&A vs Buyback Allocation
With the $540M CommonSpirit cash infusion, you repurchased $318M in stock but USPI M&A capital deployment wasn't heavily highlighted. Are you pulling back on Ambulatory center acquisitions in favor of share repurchases due to inflated ASC valuations?